Follow Us:

social twitter box white 32 social facebook box blue 32social linkedin box blue 32ISN Blog

Saturday, 24 October 2015 12:41

Dapagliflozin reduces albuminuria on top of RAS blockade in type 2 diabetic patients with moderate renal impairment

By  Davide Sjostrom
Rate this item
(0 votes)

This Presentation was given by Davide Sjostrom, from AstraZeneca, Mölndal, Sweden. It was presented at the World Congress of Nephrology 2015 in Cape Town during Session 7: Diabetic nephropathy: New insights from the bench to the bedside

 

Additional Info

  • Language: English
  • Contains Audio: Yes
  • Content Type: Presentations
  • Source: ISN
  • Event: WCN 2015
  • Year: 2015
  • Members Only: No
Read 924 times

Global Operations Center

Rue des Fabriques 1
1000 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact

               

Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact